CureVac, GSK's Bivalent MRNA Vaccine Candidate Highly Effective Against COVID-19 Variants

Retrieved on: 2022-04-21 13:18:11

Tags for this article:

Clinical trials

COVID-19 vaccination in the United States

RNA vaccines

COVID-19 pandemic in South Africa

COVID-19 pandemic by country

SARS-CoV-2 Omicron variant

Vaccine

GlaxoSmithKline plc

CureVac N.V.

Click the tags to see associated articles and topics

CureVac, GSK's Bivalent MRNA Vaccine Candidate Highly Effective Against COVID-19 Variants. View article details on HISWAI: https://www.rttnews.com/3277244/curevac-gsk-s-bivalent-mrna-vaccine-candidate-highly-effective-against-covid-19-variants.aspx

Excerpt

Despite containing only half the dose per variant-mRNA, the combined Beta/Delta candidate elicited neutralizing antibody titers fully comparable ...

Article found on: www.rttnews.com

View Original Article